本发明涉及组蛋白脱乙酰基酶的抑制。
The invention relates to the inhibition of histone deacetylase.
本发明提供了用于抑制组蛋白脱乙酰基酶酶活性的化合物和方法。
The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity.
为了逆转记忆遗失，医生在复合物中添加了组蛋白脱乙酰基酶抑制物。
To reverse the memory loss, doctors inject a compound called a histone deacetylase inhibitor.
本发明涉及作为组蛋白脱乙酰基酶（HDAC）抑制剂的异羟肟酸衍 生物。
The present invention relates to hydroxamic acid derivatives that are inhibitors of histone deacetylase (HDAC).
SITR 1是一种组蛋白脱乙酰基酶，一种能够阻断来自调节基因的转录因子的蛋白质。
SITR1 is a histone deacetylase, a protein that blocks transcription factors from regulating genes.
目的：临床试验中对组蛋白脱乙酰基酶阻滞剂(HDACi)的研究目的在于诱导细胞分化，生长停止，和肿瘤细胞的凋亡。
Purpose: Histone deacetylase inhibitors (HDACi) are being studied in clinical trials with the aim to induce cellular differentiation, growth arrest, and apoptosis of tumor cells.
组蛋白脱乙酰基酶与组蛋白脱乙酰基酶抑制剂通过对组蛋白乙酰化水平的调控，影响特定基因的表达，改变细胞周期的进程。
HDAC and histone deacetylase inhibitors (HDI) can affect expression of some specific genes and induce cell differentiation growth arrest and apoptosis through regulating histone acetylation level.
组蛋白脱乙酰基酶抑制剂已被证实具有抗肿瘤作用，多种有关组蛋白脱乙酰基酶抑制剂的药物临床试验正在进行中，以期成为治疗宫颈癌的一个新方向。
HDI has been proved to have antitumor activities and a number of clinical trials relating to HDI are in progress. It is expected that HDI becomes a new therapy of cervical cancer.
组蛋白脱乙酰基酶抑制剂已被证实具有抗肿瘤作用，多种有关组蛋白脱乙酰基酶抑制剂的药物临床试验正在进行中，以期成为治疗宫颈癌的一个新方向。
HDI has been proved to have antitumor activities and a number of clinical trials relating to HDI are in progress. It is expected that HDI becomes a new therapy of cervical cancer.
应用推荐